|
rs17429138
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A statistically significant association between adenocarcinoma risk and SNP genotype was shown: rs10937405, OR = 1.21, P = 1.82 × 10(-4); rs17429138, OR = 1.23, P = 7.49 × 10(-5); and rs4396880, OR = 1.21, P = 2.03 × 10(-4).
|
21610222 |
2011 |
|
rs4396880
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A statistically significant association between adenocarcinoma risk and SNP genotype was shown: rs10937405, OR = 1.21, P = 1.82 × 10(-4); rs17429138, OR = 1.23, P = 7.49 × 10(-5); and rs4396880, OR = 1.21, P = 2.03 × 10(-4).
|
21610222 |
2011 |
|
rs2736100
|
|
|
0.080 |
GeneticVariation |
BEFREE |
A statistically significant association between lung cancer risk and 5p15.33 genotypes was found: rs2736100 (odds ratio = 0.78, 95% confidence interval: 0.63-0.97; P = 0.02), rs4975616 (odds ratio = 0.69, 95% confidence interval: 0.55-0.85; P = 7.95 x 10(-4)), primarily for adenocarcinoma.
|
19955392 |
2010 |
|
rs4975616
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A statistically significant association between lung cancer risk and 5p15.33 genotypes was found: rs2736100 (odds ratio = 0.78, 95% confidence interval: 0.63-0.97; P = 0.02), rs4975616 (odds ratio = 0.69, 95% confidence interval: 0.55-0.85; P = 7.95 x 10(-4)), primarily for adenocarcinoma.
|
19955392 |
2010 |
|
rs766779326
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A total of three heterozygous missense ESR1 mutations, p.K303R (c.908A>G), p.T311M (c.932C>T) and p.Y537C (c.1610A>G), were identified in 3/207 (1.4%) cervical squamous cell carcinoma samples, which were absent in 27 adenosquamous carcinomas and 26 adenocarcinomas samples.
|
31452755 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.
|
17649787 |
2007 |
|
rs401681
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Additionally, in a subgroup analysis by histology type, the CLPTM1L rs401681 polymorphism was found to significantly decrease the risks of both adenocarcinoma and squamous cell carcinoma of the lung in all genetic models.
|
24634236 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation.
|
31363481 |
2019 |
|
rs2736100
|
|
|
0.080 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs401681
|
|
|
0.040 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs139852726
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs61748181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs112290073
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs138895564
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)).
|
26590902 |
2016 |
|
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
After microdissecting and testing the adenocarcinoma and neuroendocrine components separately, it was found that the adenocarcinoma was positive for KRAS G12C mutation and the neuroendocrine component was positive for KRAS G12D mutation.
|
27597976 |
2016 |
|
rs121913529
|
|
|
0.070 |
GeneticVariation |
BEFREE |
After microdissecting and testing the adenocarcinoma and neuroendocrine components separately, it was found that the adenocarcinoma was positive for KRAS G12C mutation and the neuroendocrine component was positive for KRAS G12D mutation.
|
27597976 |
2016 |
|
rs79184941
|
|
|
0.010 |
GeneticVariation |
BEFREE |
All 3 mutations were S252W and occurred in endometrioid (type I) adenocarcinomas.
|
21285871 |
2011 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All tumors had adenocarcinoma histology, and 20 patients (62.5 %) had an L858R mutation.
|
26003540 |
2015 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although 19-deletion and L858R were the most common EGFR mutations, there was no difference of EGFR mutation in pathological subtypes of adenocarcinoma.
|
27032467 |
2016 |